The estimated Net Worth of Peter Gray is at least $3.42 Milhão dollars as of 11 August 2023. Mr. Gray owns over 1,241 units of Jazz Pharmaceuticals plc stock worth over $1,689,229 and over the last 12 years he sold JAZZ stock worth over $1,173,827. In addition, he makes $557,573 as Independent Director at Jazz Pharmaceuticals plc.
Peter has made over 9 trades of the Jazz Pharmaceuticals plc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 1,241 units of JAZZ stock worth $171,457 on 11 August 2023.
The largest trade he's ever made was exercising 8,000 units of Jazz Pharmaceuticals plc stock on 18 August 2022 worth over $442,240. On average, Peter trades about 1,042 units every 201 days since 2013. As of 11 August 2023 he still owns at least 16,068 units of Jazz Pharmaceuticals plc stock.
You can see the complete history of Mr. Gray stock trades at the bottom of the page.
Peter Gray serves as Independent Director of the Company. Mr. Gray currently serves as Chairman of the board of directors of UDG Healthcare plc, an international provider of healthcare services. He is also Chairman of two privately-held companies providing outsourced services to the biopharma industry and Chairman of a non-profit educational establishment. In September 2011, Mr. Gray retired from his position as Chief Executive Officer of ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, which he held since November 2002. At ICON plc, Mr. Gray previously served as Group Chief Operating Officer from June 2001 to November 2002 and Chief Financial Officer from June 1997 to June 2001. From November 1983 to November 1989, Mr. Gray served as senior financial officer at Elan Corporation plc, a pharmaceutical company. Mr. Gray holds a degree in law from Trinity College Dublin and qualified as a chartered accountant in 1981. Based on his experience as Chief Executive Officer and Chief Financial Officer of ICON plc, Mr. Gray brings to our board of directors and audit committee over 30 years of experience in financial and operational management within the pharmaceutical industry.
As the Independent Director of Jazz Pharmaceuticals plc, the total compensation of Peter Gray at Jazz Pharmaceuticals plc is $557,573. There are 12 executives at Jazz Pharmaceuticals plc getting paid more, with Bruce Cozadd having the highest compensation of $14,713,600.
Peter Gray is 65, he's been the Independent Director of Jazz Pharmaceuticals plc since 2013. There are 1 older and 27 younger executives at Jazz Pharmaceuticals plc. The oldest executive at Jazz Pharmaceuticals plc is Catherine Sohn, 67, who is the Independent Director.
Peter's mailing address filed with the SEC is 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, L2, .
Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over $1,513,676,247 worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth $25,188,964 . The most active insiders traders include Michael W Michelson, Patrick G Enright, eJp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of $5,162,934. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth $152,703.
jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni
Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include: